10x Genomics announced Atera, a new in situ spatial biology platform positioned to deliver whole-transcriptome spatial analysis with single-cell sensitivity at scale. The company said Atera is engineered to support large-scale studies in both fresh-frozen and FFPE tissue while removing prior tradeoffs between scale, sensitivity, and gene selection. 10x plans to debut Atera with AACR Annual Meeting 2026 data, including early access results associated with Carl June’s opening plenary. The announcement frames Atera as a measurement shift toward mapping gene expression and cellular states in intact tissue at high resolution. Atera’s launch adds pressure to rival spatial technology vendors as labs seek platforms that can handle broader clinical and translational specimen types without sacrificing performance.